Clinical trial OSE 172C101
An open-label phase 1 dose finding study of BI 765063, a monoclonal antibody (mAb) antagonist of SIRPa, as single agent and in combination with BI 754091, a programmed death-1 (PD-1) mAb, to characterize safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy in patients with advanced solid tumors
| Organ | Multiple |
|---|---|
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 1 |
| Academic trial | Non |
| Sponsor | OSE Immunotherapeutics |
| EudraCT Identifier | 2018-003830-34 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03990233 |
| Inclusion criteria | SIRP-alpha polymorphism V1/V1 or V1/V2 |
| Last update |